$RDHL - FDA Approved today RHB-105

RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults,
targeting more than two million patients estimated to be treated for H. pylori infection annually

Š Talicia® is the first and only FDA approved rifabutin-based H. pylori therapy and is designed to address the high
and growing bacterial resistance and diminished efficacy of clarithromycin-based standard-of-care therapy
Š H. pylori affects approximately 35% of U.S. adult population; it is classified as a Group I carcinogen and is the
strongest risk factor for the development of peptic ulcer disease, gastritis and non-cardia gastric cancer
Š Talicia® is eligible for 8 years of U.S. market exclusivity under QIDP designation, in addition to patent
protection extending until 2034
Š Debt-free balance sheet with approximately $59 million in cash and short-term investments following a recent
strategic investment by Cosmo Pharmaceuticals
Š RedHill will host Investor and Analyst day and live webcast on November 22, 2019 to present its planned
commercial launch of Talicia® and Aemcolo®

Technically - 2 resistance at 8.54 and 9.57 (Above is the moon)